종양학 기반 In-Vivo CRO 시장 보고서 : 적응증, 모델, 용도, 지역별(2025-2033년)

The global oncology based in-vivo CRO market size reached USD 1.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.4 Billion by 2033, exhibiting a growth rate (CAGR) of 6.55% during 2025-2033. The rising prevalence of cancer, regulatory compliances, ongoing technological advancements, and the surging demand for personalized medicines are driving the market growth.

Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.

Oncology Based In-Vivo CRO Market Trends:

The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.

Key Market Segmentation:

Breakup by Indication:

• Blood Cancer
• Solid Tumors
• Others

Breakup by Model:

• Syngeneic
• Xenograft
• Patient Derived Xenograft (PDX)
• Others

Breakup by Application:

• Hospitals
• Rehabilitation Centers

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

Key Questions Answered in This Report

• 1.What was the size of the global oncology based in-vivo CRO market in 2024?
• 2.What is the expected growth rate of the global oncology based in-vivo CRO market during 2025-2033?
• 3.What are the key factors driving the global oncology based in-vivo CRO market?
• 4.What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
• 5.What is the breakup of the global oncology based in-vivo CRO market based on the indication?
• 6.What is the breakup of the global oncology based in-vivo CRO market based on the model?
• 7.What are the key regions in the global oncology based in-vivo CRO market?
• 8.Who are the key players/companies in the global oncology based in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Oncology Based In-Vivo CRO Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Blood Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Solid Tumors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Model

• 7.1 Syngeneic
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Xenograft
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Patient Derived Xenograft (PDX)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Rehabilitation Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Champions Oncology Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Charles River Laboratories International Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Crown Bioscience Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Eurofins Scientific
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Evotec SE
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 ICON Plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Living Tumor Laboratory
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Taconic Biosciences Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 The Jackson Laboratory
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 WuXi AppTec
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
  • 14.3.12 Xentech
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio